Figure 4 | Cell Death & Disease

Figure 4

From: C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo

Figure 4

PI3K/AKT inhibition sensitizes cancer cell to TSA induced cell death/apoptosis in vitro. L3.6 was transfected with either control or AKT1/2 shRNA and cultured for 48 h, successfully transfected cells were selected by puromycin(1 μM). AKT1/2 expression levels were detected in the stable cells (a). Control cells and AKT1/2 shRNA stable L3.6 cells were then treated with 200 ng/ml of TSA and cell viability was detected by MTT assay (b). L3.6 cell was either left untreated or treated with AKTi (10 μM) for 2 h; AKT and downstream mTOR activation were detected by western blot using commercially available antibodies as indicated (c). L3.6 cell was pretreated with AKTi (10 μM) for 2 h, followed by 200 ng/ml of TSA treatment; cell death was detected by MTT assay (d). WT and AKT1/2 double-knockout MEFs were treated with 200 ng/ml of TSA for 72 h, the cell viability was detected by MTT assay (e), cell apoptosis was detected by Hoechst staining at 36 h after TSA treatment and apoptosis rate was quantified in (f). Data are presented as the mean±S.D. for three independent experiments. Experiments in this figure were repeated at least three times and similar results were obtained. *P<0.05 versus that indicated in the figure (ANOVA)

Back to article page